Mirxes Secures $50 Million Series D Funding to Advance Multi-Cancer Early Detection Pipeline and Files for Hong Kong IPO

VCBeat learned at the earliest opportunity,MirxesHoldings Limited ((hereinafter referred to as MiRXES)) is aLeading RNA Technology company, focused onInnovationBloodCancerDevelopment of Early Screening Products and Services, andPromotion。MiRXES this month24DaySuccessfully Completed D round of financing, with a total funding amount of5000 USD 10,000. This fundPlaceAccelerationMiRXESAtR&D of the cancer early screening pipeline, and vigorously promote the companyInAsia-PacificKey MarketsCommercialization of。

This timeDround of financing received strong support from both new and existing investors, includingFupu Capital (Zhejiang Anji Economic Development ZoneGuidance Fund), Singapore Economic Development BoardDedicated Investment Fund (EDBI，Wholly owned by the Singapore Economic Development Board）, Singapore Agency for Science, Technology and Research (A*STAR，branch of a public R&D institution under the Singapore Ministry of Trade and Industry),Japan ThreeIi Shoji Co., Ltd.andNuohuiVenture Capital Fund.

Dr. Zhou Lihan, Co-founder and CEO of MiRXES, stated, “Completing a new round of $50 million in financing amid a challenging macroeconomic environment further underscores the significance of our industry-leading miRNA detection technology platform in addressing the clinical and socioeconomic burden of cancer, while continuously solidifying MiRXES’ leadership in the global field of early cancer screening technologies. We are honored to have the support and trust of both existing and new investors. We will fully accelerate commercialization in key Asia-Pacific markets and continue to advance our efforts in blood-based multi-cancer early detection.”

The new investment will primarily be used to increase the penetration and repeat usage rates of MiRXES’ flagship product—a blood-based early screening test for gastric cancer—in key Asia-Pacific markets, including Southeast Asia, China, and Japan. It will also accelerate the development and commercialization of MiRXES’ mature clinical pipeline, including blood-based screening assays for colorectal cancer and lung cancer, as well as the CADENCE multi-cancer early detection test. The CADENCE project leverages the company’s industry-leading miRNA technology combined with multi-omics biomarker detection, aiming to develop a blood-based early screening test covering nine types of cancer.

In addition to securing its Series D financing, MiRXES announced that it has submitted an A1 listing application to The Stock Exchange of Hong Kong Limited (“HKEX”) in accordance with the requirements of Chapter 18A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The company aims to build an industry-leading multi-omics technology enterprise centered on RNA technology, vigorously promote the commercialization of its blood-based cancer early screening products in the Asia-Pacific market, and establish a leading gene-specific testing platform for comprehensive cancer care in Southeast Asia, thereby addressing the substantial clinical demand in the region. These milestone developments will provide investors with greater opportunities and further solidify MiRXES’s position in the industry.

With robust financial reserves, expanding market share, and the support of both new and established strategic partners, MiRXES is well-positioned to advance its mission of making early disease detection convenient and accessible worldwide. These developments underscore MiRXES’ unwavering commitment to reducing the cancer burden and lowering healthcare costs by leveraging innovative RNA tests for early disease detection, thereby creating a healthier future for society.

MiRXES, founded in 2014, is a leading RNA diagnostics technology company dedicated to providing blood-based early cancer screening products and services globally. The company has developed and commercialized precise, non-invasive, and affordable blood-based miRNA diagnostic reagents for the early screening of cancer and other diseases.

MiRXES's Gastric Cancer Screening Product (GASTROClear^TM/MiXiaoWei^TM) is a molecular diagnostic kit based on blood microRNA. It has been approved in Singapore and received EU CE marking, and is currently undergoing a prospective clinical trial involving nearly 10,000 participants in China. According to industry reports, MiRXES is the first and only company globally to have obtained regulatory approval for an in vitro diagnostic (IVD) product for molecular gastric cancer screening. To lead the global initiative in early cancer screening, the company has launched its flagship program—the CADENCE (Cancer Detected Early caN be CurEd) project—leveraging its industry-leading RNA technology platform, extensive expertise in PCR diagnostics, and ultra-high-throughput next-generation sequencing (NGS) capabilities to develop a blood-based multi-cancer early detection test.